Summary of Mount Logan Capital (PYCF.F) 2025 Extraordinary General Meeting Company Overview - **Company**: Mount Logan Capital Inc - **Meeting Date**: August 29, 2025 - **Format**: Virtual meeting Key Points Discussed Meeting Structure and Voting Process - The meeting was conducted online, allowing registered shareholders and proxy holders to submit questions via instant messaging [2][21] - Voting was conducted electronically, with registered shareholders and proxy holders able to vote on each item of business after presentations [3][15] - A quorum of shareholders was confirmed to be present, allowing the meeting to proceed [8] Resolutions Approved 1. **Arrangement Resolution**: - Approval of a plan of arrangement to continue Mount Logan out of Ontario to Delaware and convert it to a limited liability company [9][19] - Required at least two-thirds of votes cast to pass [10] 2. **Merger Agreement**: - Approval of a merger agreement involving Mount Logan and other entities, with Mount Logan as the surviving company [11][19] - Required greater than 50% of all issued and outstanding common shares to pass [12] 3. **2025 Omnibus Incentive Plan**: - Approval of the Omnibus Incentive Plan for 2025 [14][20] - Required a majority of votes cast to pass [15] Voting Results - All resolutions were declared carried based on the scrutineers' report, confirming the requisite number of shares voted in favor of each resolution [19][20] Additional Information - The meeting materials, including the joint proxy statement and prospectus, were made available to shareholders prior to the meeting [6] - The results of the voting will be published on SEDAR and through a press release following the meeting [20] Conclusion - The formal portion of the meeting concluded without any questions from shareholders, and the meeting was adjourned [21][22]

Transaction Overview - The company plans to acquire 100% equity of Tianjin Huarui Leifang Technology Co., Ltd. from its wholly-owned subsidiary Beijing Huaqing Ruida Technology Co., Ltd. for a price of 0 yuan, making Huarui Leifang a wholly-owned subsidiary of the company [1][5] - This equity transfer is part of the company's strategy to streamline the organizational structure of its radar and aerospace electronics sectors, reduce management levels, and lower management costs [5][6] Financial Data of Huaqing Ruida - As of December 31, 2024, Huaqing Ruida had total assets of 816.6151 million yuan, total liabilities of 377.2729 million yuan, and owner's equity of 439.3422 million yuan, with a revenue of 309.3091 million yuan and a net profit of 20.0581 million yuan for the year [3][4] Financial Data of Huarui Leifang - As of December 31, 2024, Huarui Leifang had total assets of 34.6782 million yuan, total liabilities of 121.5776 million yuan, and negative owner's equity of -86.8994 million yuan, with a revenue of 14.8960 million yuan and a net loss of -6.4241 million yuan for the year [4] - As of June 30, 2025, Huarui Leifang's total assets were 42.7688 million yuan, total liabilities were 111.8780 million yuan, and negative owner's equity was -69.1092 million yuan, with a revenue of 3.2581 million yuan and a net loss of -2.2098 million yuan for the first half of the year [4] Impact on the Company - The adjustment of the subsidiary's equity structure will not change the scope of the company's consolidated financial statements and will not affect the company's normal operations [6] - The transaction aligns with the company's overall strategic planning and operational needs, ensuring no harm to the interests of the company and its shareholders, particularly minority shareholders [6]

Core Viewpoint - The company, Peking University Pharmaceutical Co., Ltd., is undergoing significant changes, including a shift in its actual controller and plans to rename itself and its subsidiaries to reflect this change, moving away from its association with Peking University [1] Group 1: Corporate Changes - The company announced the initiation of name changes for itself and its subsidiaries due to a change in actual control, with Xu Xiren now being the actual controller [1] - The company aims to clarify its current control relationships and align with its operational and business development needs through these name changes [1] Group 2: Strategic Adjustments - To optimize resource allocation and enhance operational efficiency, the company plans to strategically adjust its existing manufacturing system and establish a manufacturing subsidiary based in its production center in Chongqing [1][2] - The manufacturing subsidiary will focus on the production segment, allowing for centralized resource allocation and improved utilization, thereby enhancing the company's competitive edge in generic drug production [2] Group 3: Operational Efficiency - The establishment of the manufacturing subsidiary will create a clear framework for operational responsibilities, management authority, and performance targets, fostering a more effective incentive mechanism [2] - This structure is expected to motivate the manufacturing team to improve production efficiency, reduce costs, and enhance product quality, ultimately creating greater value for the company [2]